Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Hospitalization 45% Improvement Relative Risk c19early.com/pl Dryden-Peterson et al. Paxlovid for COVID-19 EARLY Favors paxlovid Favors control
Dryden-Peterson, 30,322 patient paxlovid early treatment study: 45% lower hospitalization [p=0.002] https://c19p.org/drydenpeterson
copied to clipboard
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
Dryden-Peterson et al., medRxiv, doi:10.1101/2022.06.14.22276393 (Preprint)
16 Jun 2022    Source   PDF   Share   Tweet
IPW retrospective 30,322 age 50+ outpatients in the USA, showing lower hospitalization with paxlovid treatment.
risk of hospitalization, 45.0% lower, RR 0.55, p = 0.002, treatment 40 of 6,036 (0.7%), control 232 of 24,286 (1.0%), propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dryden-Peterson et al., 6/16/2022, retrospective, USA, North America, preprint, 12 authors, study period 1 January, 2022 - 15 May, 2022.
Contact: sldrydenpeterson@bwh.harvard.edu.
All Studies   All Outcomes
This PaperPaxlovidAll
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit